SCHEMBL29327692

SCHEMBL29327692

N#Cc1ccc(S(=O)(=O)C(F)(F)F)c(C(=O)Nc2ccc3oc(-c4ccccc4Br)nc3c2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 12/20 0.54
▸ TP53 P04637 5/20 0.54
▸ NPC1 O15118 4/20 0.54
▸ RAB9A P51151 4/20 0.54
▸ SMN1; SMN2 Q16637 4/20 0.54
▸ KDM4E B2RXH2 3/20 0.54
▸ HPGD P15428 2/20 0.54
▸ NFKB1 P19838 2/20 0.54
▸ NFKB2 Q00653 2/20 0.54
▸ RELA Q04206 2/20 0.54
▸ HSD17B10 Q99714 2/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ LMNA P02545 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ PPARG P37231 2/20 0.51
▸ KMT2A Q03164 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ RXFP1 Q9HBX9 4/20 0.49
▸ KDR P35968 1/20 0.47
▸ THRB P10828 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29327592 0.91 MAPT (0.59) MAPTTP53NPC1RAB9ASMN1; SMN2
SCHEMBL29327681 0.90 MAPT (0.55) MAPTTP53NPC1RAB9ASMN1; SMN2
SCHEMBL29327677 0.84 PPARG (0.59) MAPTTP53NPC1RAB9ASMN1; SMN2
SCHEMBL29327687 0.83 PPARG (0.55) MAPTTP53NPC1RAB9ASMN1; SMN2
SCHEMBL29327675 0.83 MAPT (0.55) MAPTTP53NPC1RAB9ASMN1; SMN2
SCHEMBL29327584 0.82 MAPT (0.58) MAPTTP53NPC1RAB9ASMN1; SMN2
SCHEMBL29327683 0.82 PPARG (0.72) MAPTTP53SMN1; SMN2PPARGRXFP1
SCHEMBL29327701 0.82 PPARG (0.55) MAPTTP53NPC1RAB9ASMN1; SMN2
SCHEMBL29327823 0.81 MAPT (0.57) MAPTTP53NPC1RAB9ASMN1; SMN2
SCHEMBL29327752 0.80 MAPT (0.57) MAPTTP53NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF PPARG, PPARA, PPARD MAPT 4591/4885TP53 1398/4885NPC1 695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback